Pipeline - Scailyte

Scailyte is dedicated to developing a proprietary pipeline of impactful diagnostic and predictive/CDx solutions that directly serve precision medicine. We harness insights from carefully curated patient cohort data using our ScaiVision AI to discover and validate these clinical assets, with a clear focus on translatability. Our in-house projects, such as the AIomics IBD program, exemplify this commitment. Our extensive experience and fast, translatable platform also includes strategic collaborations with drug developers — analyzing their early trial data in immunology, oncology, and cell therapy to dissect MoA and find predictive biomarkers and de-risk their clinical programs. This expertise not only enriches our pipeline development but also presents opportunities for targeted partnerships and licensing of Scailyte’s unique assets.

Indication	Clinical Use	Tissue
Cutaneous T Cell Lymphoma (CTCL)	Diagnosis	PBMCs
Endometriosis	Diagnosis	PBMCs Endometrium
Cell Therapy	Manufacturing optimization	PBMCs
Pan-cancer	Prediction of metastasis	Tumor biopsy
CAR T Therapy	Prediction of Response & AE	Infusion Product
Immunotherapy for IBD	MoA; Prediction of Response	PBMCs Tissue biopsy

Our Discovery Pipeline is engineered to tackle complex diseases with significant unmet needs, with a strong focus on advancing immunotherapies. We demonstrate broad technical versatility, working with any kind of tissue sample and various data types to achieve single-cell resolution for deep biological understanding. This enables the discovery of powerful signatures tailored to diverse and critical clinical endpoints—from diagnosis and prognosis, to predicting therapy response and adverse reactions, or understanding treatment MoA. Crucially, Scailyte excels in translating these sophisticated discoveries into practical, clinically-ready assay prototypes for accessible platforms like flow cytometry or PCR, accelerating their path to patient impact.

AIomics IBD Program: Revolutionizing IBD Treatment with Predictive AI & Multimodal Data

The IBD Challenge

Current treatments for Inflammatory Bowel Disease (IBD), including widely used anti-TNF therapies, hit a therapeutic ceiling with response rates often capped around 30%. This significant limitation forces the pharmaceutical industry to urgently find robust methods for identifying specific patient subpopulations more likely to respond, and to pioneer therapies that can truly outperform today’s standard of care. Addressing this for anti-TNF therapies is a critical first step, with broader implications for other IBD treatments.

Scailyte’s Solution

Unique Multimodal Data:

We generate and analyze unparalleled, well-annotated, high-resolution multimodal data from retrospective and prospective IBD patient cohorts, integrating scRNAseq, spatial transcriptomics, genomic, and microbiome insights.

Our Explainable AI:

ScaiVision applies its unbiased, proprietary algorithm to this rich data, identifying complex and highly predictive molecular signatures for treatment response and resistance.

A Clinically Translatable Approach:

Discoveries are not made in isolation; we focus on translating these intricate signatures into practical biomarker assays and clinical decision support systems. The impact and successful clinical translation of this program are powerfully supported by our continuously expanding IBD clinical and industry network.

Scailyte thrives on collaboration and views strong partnerships as essential to accelerating precision medicine. We approach every engagement with flexibility, aiming to act as an extension of your team, moving from initial proof-of-concept to strategic impact. Beyond our internal pipeline, we engage in focused collaborations to accelerate the impact of precision medicine. With academic partners, we aim to generate unique, large-scale omics datasets and address unmet clinical needs related to established therapies, often leading to groundbreaking joint publications. With our industry partners, we strategically apply our platform to de-risk clinical programs by elucidating drug MoA and predicting response to therapies in development, particularly leveraging our fast, translatable approach for early-stage trial data. Furthermore, Scailyte offers licensing opportunities for our curated unique datasets and internally developed clinical assay prototypes to organizations that share our commitment to advancing patient care.

Making Clinical Impact: Inside Scailyte's Discovery Pipeline

Program Spotlight